Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06856213 |
| Title | Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX) |
| Acronym | ERBIOTAX |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ESP |